Active substance | dapagliflozin |
Holder | AstraZeneca NV/SA |
Status | closed |
Indication | Treatment of chronic kidney disease |
Public documents | Approbation |
Approbation Amendment | |
Information for the patient | |
Informed consent | |
Last update | 02/12/2022 |
Active substance | dapagliflozin |
Holder | AstraZeneca NV/SA |
Status | closed |
Indication | Treatment of chronic kidney disease |
Public documents | Approbation |
Approbation Amendment | |
Information for the patient | |
Informed consent | |
Last update | 02/12/2022 |